Metastatic pancreatic ductal adenocarcinoma (mPDAC) is a highly aggressive, lethal form of pancreatic cancer that accounts for more than 90% of pancreatic cancer cases.

At ASCO 2025, Actuate gave an oral presentation on positive Phase 2 combination data for elraglusib, highlighting its potential to enhance anti-tumour activity by targeting key resistance pathways and immune mechanisms in previously untreated patients with mPDAC.

In a post-ASCO pharmaphorum podcast, Dan Schmitt, CEO of Actuate, discussed the data, as well as the Congress as a whole, and his hopes for the future of oncology more generally.

You can also listen to episode 195a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.